TrialSignal transduction and targeted therapy2023

Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study.

Si-Yang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.